Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins using Mass Spectrometry

Atlas Antibodies AB, a leading supplier of advanced research reagents, announced today the introduction of pre-quantified QPrEST™ Protein Standards for absolute quantification of proteins in biological samples such as cell lysate and plasma using liquid chromatography (LC)–mass spectrometry (MS).


Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

QPrESTs consists of 50-150 amino acids identical to a part of the corresponding human protein. They are produced recombinantly in the presence of stable isotope-labeled (i.e. heavy) amino acids to generate protein standards. Targeted proteomics is a method allowing absolute quantification of the proteins of interest by comparing the MS signal intensities of the stable isotope standard with an endogenous peptide that is generated upon proteolytic digestion of the target protein.

One of the advantages of QPrESTs over other available protein standards is that they are added to the sample early in the workflow, prior to proteolytic digestion. The shared amino acid sequence of the QPrEST and the endogenous protein enables the QPrEST to correct for variation introduced during sample digestion, thereby increasing accuracy in quantification.

John Daicic, CEO of Atlas Antibodies, commented: “Just like our antibodies, the new, pre-quantified QPrEST standards are available for the vast majority of the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo